Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Comment
  • Published:

Translation of tissue-engineering innovations requires a connected ecosystem

Nature Reviews Bioengineering volume 1, pages 879–881 (2023)Cite this article

Subjects

The potential of tissue engineering to deliver clinical advances hinges on a connected ecosystem that includes academics, funding agencies, entrepreneurs, investors, the pharmaceutical industry and regulatory bodies. Open dialog on goals and risks across these stakeholders is key to implementing bioengineered tissue models in drug development and tissue therapies.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

References

  1. Ingber, D. E. Human organs-on-chips for disease modelling, drug development and personalized medicine. Nat. Rev. Genet. 23, 467–491 (2022).

    Article  Google Scholar 

  2. Vulto, P. & Joore, J. Adoption of organ-on-chip platforms by the pharmaceutical industry. Nat. Rev. Drug Discov. 20, 961–962 (2021).

    Article  Google Scholar 

  3. Proctor, W. R. et al. Utility of spherical human liver microtissues for prediction of clinical drug-induced liver injury. Arch. Toxicol. 91, 2849–2863 (2017).

    Article  Google Scholar 

  4. Ewart, L. et al. Performance assessment and economic analysis of a human liver-chip for predictive toxicology. Commun. Med. 2, 154 (2022).

    Article  Google Scholar 

  5. Peters, M. F. et al. Human 3D gastrointestinal microtissue barrier function as a predictor of drug-induced diarrhea. Toxicol. Sci. 168, 3–17 (2019).

    Article  Google Scholar 

  6. Fabre, K. et al. Introduction to a manuscript series on the characterization and use of microphysiological systems (MPS) in pharmaceutical safety and ADME applications. Lab Chip 20, 1049–1057 (2020).

    Article  Google Scholar 

  7. Langer, R. & Vacanti, J. P. Tissue Engineering. Science 260, 920–926 (1993).

    Article  Google Scholar 

  8. Atala, A., Kasper, F. K. & Mikos, A. G. Engineering complex tissues. Sci. Transl. Med. 4, 160rv12 (2012).

    Article  Google Scholar 

  9. Tollefson, J. The rise of ‘ARPA-everything’ and what it means for science. Nature 595, 483–484 (2021).

    Article  Google Scholar 

  10. Higgins, R. F., LaMontagne, S. & Kazan, B. Vertex Pharmaceuticals and the Cystic Fibrosis Foundation: venture philanthropy funding for biotech. HBS Case Collection https://www.hbs.edu/faculty/Pages/item.aspx?num=35037 (October 2007).

Download references

Acknowledgements

The authors acknowledge all participants of the Wellcome Leap HOPE-meets-Industry event (7 December 2022) for the discussion on catalyzing bioengineering innovations.

Author information

Authors and Affiliations

  1. Human Organs, Physiology and Engineering (HOPE), Wellcome Leap, Los Angeles, CA, USA

    Annie Moisan

  2. Flagship Pioneering, Cambridge, MA, USA

    David Kolesky

  3. 3D Systems, Houston, TX, USA

    Jordan Miller

  4. Rice University, Houston, TX, USA

    Jordan Miller

  5. Complex in vitro Systems, Safety Assessment, Genentech, South San Francisco, CA, USA

    Kimberly Homan

Authors
  1. Annie Moisan
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. David Kolesky
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Jordan Miller
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Kimberly Homan
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

All authors contributed to researching data, discussing content and writing the manuscript. A.M. and K.A.H. reviewed and edited the manuscript for submission and publication.

Corresponding authors

Correspondence to Annie Moisan or Kimberly Homan.

Ethics declarations

Competing interests

The authors declare no competing interests.

Additional information

Related links

Advanced Regenerative Manufacturing Institute: https://www.armiusa.org/

Advanced Research and Invention Agency (Aria): https://www.aria.org.uk/

Advanced Research Projects Agency for Health (ARPA-H): https://arpa-h.gov/

American Society for Testing and Materials: https://www.astm.org/

Defense Advanced Research Projects Agency (DARPA): https://www.darpa.mil/

EMA strategic vision: https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/ema-regulatory-science-2025-strategic-reflection_en.pdf

Emergency Use Authorization: https://www.fda.gov/emergency-preparedness-and-response/mcm-legal-regulatory-and-policy-framework/emergency-use-authorization

European Organ-on-Chip Society: https://euroocs.eu/

FDA Alternative Methods working group: https://www.fda.gov/science-research/about-science-research-fda/advancing-alternative-methods-fda

FDA Modernization Act 2.0: https://www.nabr.org/about-nabr/news/nabrs-press-statement-fda-modernization-act-20

Federal Agency for Disruptive Innovations (SPRIN-D): https://www.sprind.org/en/

Innovative Science and Technology Approaches for New Drugs: https://www.fda.gov/drugs/drug-development-tool-ddt-qualification-programs/innovative-science-and-technology-approaches-new-drugs-istand-pilot-program

Institute of Human Biology: https://institutehumanbiology.com/

IQ Microphysiological Systems Affiliate: https://www.iqmps.org/

International Microphysiological System Society: https://impss.org/

Moonshot Research and Development Program: https://www8.cao.go.jp/cstp/english/moonshot/top.html

National Centre for Advancing Translational Sciences: https://ncats.nih.gov/

Partnership between Semma Therapeutics and the Juvenile Diabetes Research Foundation: https://t1dfund.org/news/semma-therapeutics-receives-investment-from-jdrf-t1d-fund/

Right to Try Act: https://www.fda.gov/patients/learn-about-expanded-access-and-other-treatment-options/right-try

Tissue Chip for Drug Screening program: https://ncats.nih.gov/tissuechip

Tissue chip testing centers: https://ncats.nih.gov/tissuechip/projects/centers

Wellcome Leap: https://wellcomeleap.org/

Wellcome Leap HOPE Program: https://wellcomeleap.org/hope/

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Moisan, A., Kolesky, D., Miller, J. et al. Translation of tissue-engineering innovations requires a connected ecosystem. Nat Rev Bioeng 1, 879–881 (2023). https://doi.org/10.1038/s44222-023-00111-y

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s44222-023-00111-y

Search

Advanced search

Quick links

Nature Briefing: Translational Research

Sign up for the Nature Briefing: Translational Research newsletter — top stories in biotechnology, drug discovery and pharma.

Get what matters in translational research, free to your inbox weekly. Sign up for Nature Briefing: Translational Research